

Editorial


Danger Signals and Inflammation



This special themed update includes 6 articles by experts in the field covering the role of different classes of molecules and processes involved in alerting an organism of the presence of real or perceived, external or internal, dangers that threaten its survival. These reviews address the role of purinergic signaling and immune responses in sepsis, the alarmin properties of DNA and DNA-associated nuclear proteins, the key role of damage-associated molecular patterns in inflammation and tissue repair, the potential therapeutic aspects of alarmin cytokine interleukin (IL)-33 or its inhibitors in various diseases, the role of alarmins in antitumor immunity, and nanotube formation, a rapid form of alarm signaling.¹⁻⁶ Better understanding of these danger signals, also known as alarmins, and their possible containment in case of false or sustained alarm would help prevent or treat a number of diseases.

Selye⁷ was the first to write about the stress response to explain how a mammal responds to danger to survive (the fight or flight response). Although he tried to identify a responsible hypothalamic factor, he missed corticotropin-releasing hormone (CRH),⁸ which is considered a master alarmin that mediates the effect of stress on the body, especially the skin.⁹ It is interesting that CRH also promotes inflammation,¹⁰ an evolutionary defense response¹¹ that preceded the development of the immune system. Inflammation is now known to depend on a unique, ancient,¹² multitasking cell¹³—the mast cell¹⁴—which has existed throughout the phylogenetic tree.^{15,16} The body has the ability to secrete hormonal, immune, and neural substances¹⁴ resembling the behavior of unicellular organisms dating back some 500 million years.^{17,18} In fact, Selye¹⁹ wrote in his comprehensive book *The Mast Cells* that “the so-called metachromatic corpuscles found in certain protozoa may be related to mast cells” and “the metachromatic volutin granules of yeast resemble mast cell granules.”

CRH can promote the development of skin mast cell progenitors²⁰ and stimulate skin mast cells.²¹ Human mast cells express the high affinity CRH receptor-1 (CRHR-1), activation of which leads to selective release of vascular endothelial growth factor without degranulation.²² Intradermal administration of CRH activates skin mast cells and increases vascular permeability through activation of CRHR-1 in humans.²³ In fact, stress increases the expression of CRHR-1 in bone marrow mast cells.²⁴ Moreover, CRH can be secreted from mast cells²⁵ and can stimulate the hypothalamic-pituitary axis, triggering the fight or flight reaction.^{26,27} Different life forms and tissues developed a variety of molecules to sound the alarm and keep them out of danger (**Table**). The horseshoe crab, which resembles species that existed more than 500 million years ago, survived by using defenses that involved a close interplay between the coagulation and innate immune systems.²⁸ It is, therefore, interesting that among the most potent triggers of mast cells is bradykinin, which is generated by the action of kallikrein on kininogen derived from Hageman factor XII of the clotting cascade,^{29,30} and mast cells are the richest source of the anticoagulant heparin.³¹



Theoharis C. Theoharides, MS, MPhil, PhD, MD, FAAAAI



Scan the QR Code with your phone to obtain FREE ACCESS to the articles featured in the Clinical Therapeutics topical updates or text GS2C65 to 64842. To scan QR Codes your phone must have a QR Code reader installed.

Table. Danger signals.

AMPs	Histamine	Nucleolin
Annexins	HMGB1	PAMPs
ATP	HDGF	PRRs
Cathelicidins	HSPs	SPMs
CLRs	IFNs	S100s
CRH	IL-1	Thymosins
DAMPs	IL-33	TLRs
Defensins	mtDNA	Uric acid
EDN	NAMPs	Urocortin
Galectins		

AMPs = antimicrobial peptides; CLRs = C-type lectin receptors; CRH = corticotropin-releasing hormone; DAMPs = damage-associated molecular patterns; EDN = eosinophil-derived neurotoxin; HDGF = hepatoma-derived growth factor; HMGB1 = high mobility group box 1; HSPs = heat shock proteins; IFNs = interferons; mtDNA = mitochondrial DNA; NAMPs = nanoparticle-associated molecular patterns; PAMPs = pathogen-associated molecular patterns; PRRs = pattern recognition receptors; SPMs = specialized pro-resolving mediators; TLRs = toll-like receptors;

Pattern recognition receptors,^{32,33} which include damage-associated molecular patterns, nanoparticle-associated molecular patterns, and pathogen-associated molecular patterns,³⁴ C-type lectin receptors³⁵ are major danger signals (Table) acting through activation of toll-like receptors. It is interesting that toll-like receptors are also expressed by mast cells,³⁶ activation of which allows them to augment allergic stimulation³⁷ and regulate responses to pathogens.^{38–40}

Among the recent molecules to have emerged as a key danger signal is IL-33, which has been linked to autoimmune and inflammatory diseases,^{41–43} possibly acting through mast cells.^{44,45} IL-33 augments also mast cell stimulation by the neuropeptide substance P.⁴⁶ In fact, stimulated mast cells secrete the substance P-related peptide hemokinin-1, which acts in an autocrine manner to augment their stimulation by allergic triggers.⁴⁷

Unfortunately, danger signals often go overboard, leading to a heightened or sustained alarm state that becomes deleterious to the organism. Such is the case of the autoinflammatory diseases characterized by high serum IL-1⁴⁸ and generalized sepsis associated with cytokine storms.⁴⁹ It is therefore important to explore ways that may protect the organism from overzealous alarmins with molecules such as specialized proresolving mediators,⁵⁰ high mobility group box 1,⁵¹ and microRNAs.⁵²

Theoharis C. Theoharides, MS, MPhil, PhD, MD, FAAAAI
Molecular Immunopharmacology and Drug Discovery
Department of Integrative Physiology and Pathobiology
Department of Internal Medicine, and Department of Psychiatry
School of Medicine, and Sackler School of Graduate Biomedical Sciences
Tufts University, Boston, Massachusetts

REFERENCES

1. Ledderose C, Bao Y, Kondo Y, et al. Purinergic signaling and immune responses in sepsis. *Clin Ther.* 2016;38:1054–1065.
2. Magna M, Pisetsky DS. The Alarmin Properties of DNA and DNA-Associated Nuclear Proteins. *Clin Ther.* 2016;38:1029–1041.
3. Pandolfi F, Altamura S, Frosali S, et al. Key role of DAMP in inflammation, cancer and tissue repair. *Clin Ther.* 2016;38:1017–1028.
4. Arshad MI, Khan HA, Noel G, et al. Potential therapeutic aspects of alarmin cytokine IL-33 or its inhibitors in various diseases. *Clin Ther.* 2016;38:1000–1016.

5. Nie Y, Yang D, Oppenheim JJ. Alarmins and Antitumor Immunity. *Clin Ther.* 2016;38:1042–1053.
6. Weng Z, Zhang B, Tsilioni I, et al. Nanotube formation: A rapid form of “alarm signaling”? *Clin Ther.* 2016;38:1066–1072.
7. Selye H. The stress of life, 2nd ed. New York: McGraw-Hill; 1978.
8. Slominski AT, Zmijewski MA, Zbytek B, et al. Key Role of CRF in the Skin Stress Response System. *Endocr Rev.* 2013;34:827–884.
9. Paus R, Theoharides TC, Arck PC. Neuroimmunoendocrine circuitry of the ‘brain-skin connection’. *Trends Immunol.* 2006;27:32–39.
10. Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. *N Engl J Med.* 1995;332:1351–1362.
11. McDade TW. Early environments and the ecology of inflammation. *Proc Natl Acad Sci U S A.* 2012;109(Suppl 2):17281–17288.
12. Wong GW, Zhuo L, Kimata K, et al. Ancient origin of mast cells. *Biochem Biophys Res Commun.* 2014;451:314–318.
13. Krystel-Whittemore M, Dileepan KN, Wood JG. Mast Cell: A Multi-Functional Master Cell. *Front Immunol.* 2015;6:620.
14. Theoharides TC, Valent P, Akin C. Mast Cells, Mastocytosis, and Related Disorders. *N Engl J Med.* 2015;373:163–172.
15. Crivellato E, Travan L, Ribatti D. The phylogenetic profile of mast cells. *Methods Mol Biol.* 2015;1220:11–27.
16. Ribatti D. The development of human mast cells. An historical reappraisal. *Exp Cell Res.* 2016.
17. Csaba G. The unicellular Tetrahymena as a model cell for receptor research. *Int Rev Cytol.* 1985;95:327–377.
18. Csaba G. Biogenic amines at a low level of evolution: Production, functions and regulation in the unicellular Tetrahymena. *Acta Microbiol Immunol Hung.* 2015;62:93–108.
19. Selye H. The mast cells. London: Butterworth Inc; 1965.
20. Ito N, Sugawara K, Bodo E, et al. Corticotropin-releasing hormone stimulates the in situ generation of mast cells from precursors in the human hair follicle mesenchyme. *J Invest Dermatol.* 2010;130:995–1004.
21. Donelan J, Boucher W, Papadopoulou N, et al. Corticotropin-releasing hormone induces skin vascular permeability through a neurotensin-dependent process. *Proc Natl Acad Sci USA.* 2006;103:7759–7764.
22. Cao J, Papadopoulou N, Kempuraj D, et al. Human mast cells express corticotropin-releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor. *J Immunol.* 2005;174:7665–7675.
23. Crompton R, Clifton VL, Bisits AT, et al. Corticotropin-releasing hormone causes vasodilation in human skin via mast cell-dependent pathways. *J Clin Endocrinol Metab.* 2003;88:5427–5432.
24. Theoharides TC, Petra AI, Stewart JM, et al. High serum corticotropin-releasing hormone (CRH) and bone marrow mast cell CRH receptor expression in a mastocytosis patient. *J Allergy Clin Immunol.* 2014;134:1197–1199.
25. Kempuraj D, Papadopoulou NG, Lytinas M, et al. Corticotropin-releasing hormone and its structurally related urocortin are synthesized and secreted by human mast cells. *Endocrinology.* 2004;145:43–48.
26. Matsumoto I, Inoue Y, Shimada T, et al. Brain mast cells act as an immune gate to the hypothalamic-pituitary-adrenal axis in dogs. *J Exp Med.* 2001;194:71–78.
27. Kalogeromitros D, Syrigou EI, Makris M, et al. Nasal provocation of patients with allergic rhinitis and the hypothalamic-pituitary-adrenal axis. *Annals Allergy, Asthma, Immunology.* 2007;98:269–273.
28. Delvaeye M, Conway EM. Coagulation and innate immune responses: can we view them separately? *Blood.* 2009;114:2367–2374.
29. Kaplan AP, Joseph K. Pathogenic mechanisms of bradykinin mediated diseases: dysregulation of an innate inflammatory pathway. *Adv Immunol.* 2014;121:41–89.
30. Pearce FL. Non-IgE-mediated mast cell stimulation. *Ciba Found Symp.* 1989;147:74–87.
31. Ronnberg E, Melo FR, Pejler G. Mast cell proteoglycans. *J Histochem Cytochem.* 2012;60:950–962.
32. Brines M, Cerami A. The receptor that tames the innate immune response. *Mol Med.* 2012;18:486–496.
33. Hansen JD, Vojtech LN, Laing KJ. Sensing disease and danger: a survey of vertebrate PRRs and their origins. *Dev Comp Immunol.* 2011;35:886–897.
34. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. *J Leukoc Biol.* 2007;81:1–5.
35. Kulkarni R, Jeyaseelan S. Editorial: Strangers with candy: policing the lungs with C-type lectins. *J Leukoc Biol.* 2013;94:387–389.
36. Sandig H, Bulfone-Paus S. TLR signaling in mast cells: common and unique features. *Front Immunol.* 2012;3:185.
37. Qiao H, Andrade MV, Lisboa FA, et al. FcεpsilonR1 and toll-like receptors mediate synergistic signals to markedly augment production of inflammatory cytokines in murine mast cells. *Blood.* 2006;107:610–618.
38. Abraham SN, St John AL. Mast cell-orchestrated immunity to pathogens. *Nat Rev Immunol.* 2010;10:440–452.
39. Saluja R, Metz M, Maurer M. Role and relevance of mast cells in fungal infections. *Front Immunol.* 2012;3:146.
40. Marshall JS. Mast-cell responses to pathogens. *Nat Rev Immunol.* 2004;4:787–799.
41. Theoharides TC, Petra AI, Taracanova A, et al. Targeting IL-33 in autoimmunity and inflammation. *J Pharmacol Exp Ther.* 2015;354:24–31.

42. Saluja R, Khan M, Church MK, et al. The role of IL-33 and mast cells in allergy and inflammation. *Clin Transl Allergy*. 2015;5:33.
43. Cayrol C, Girard JP. IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy. *Curr Opin Immunol*. 2014;31:31–37.
44. Moussion C, Ortega N, Girard JP. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel ‘alarmin’? *PLoS ONE*. 2008;3:e3331.
45. Enoksson M, Lyberg K, Moller-Westerberg C, et al. Mast cells as sensors of cell injury through IL-33 recognition. *J Immunol*. 2011;186:2523–2528.
46. Theoharides TC, Zhang B, Kempuraj D, et al. IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin. *Proc Natl Acad Sci U S A*. 2010;107:4448–4453.
47. Sumpter TL, Ho CH, Pleet AR, et al. Autocrine hemokinin-1 functions as an endogenous adjuvant for IgE-mediated mast cell inflammatory responses. *J Allergy Clin Immunol*. 2015;135:1019–1030.
48. Savic S, Dickie LJ, Battellino M, et al. Familial Mediterranean fever and related periodic fever syndromes/autoinflammatory diseases. *Curr Opin Rheumatol*. 2012;24:103–112.
49. Lakshmikanth CL, Jacob SP, Chaithra VH, et al. Sepsis: in search of cure. *Inflamm Res*. 2016. ahead of print.
50. Serhan CN, Chiang N, Dalli J. The resolution code of acute inflammation: Novel pro-resolving lipid mediators in resolution. *Semin Immunol*. 2015;27:200–215.
51. Gentile LF, Moldawer LL. HMGB1 as a therapeutic target for sepsis: it’s all in the timing!. *Expert Opin Ther Targets*. 2014;18:243–245.
52. Marques-Rocha JL, Samblas M, Milagro FI, et al. Noncoding RNAs, cytokines, and inflammation-related diseases. *FASEB J*. 2015;29:3595–3611.